ReviewMolecular biology reports2026
Recombinant cytokines produced in Komagataella phaffii: advances in design, production, and purification strategies.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines are small glycosylated polypeptides that orchestrate immune responses and are widely produced in recombinant form for therapeutic and research purposes. This review highlights Komagataella phaffii as an efficient host for the heterologous expression of recombinant cytokines from human and other species. A systematic search of PubMed, Scopus, and Web of Science identified studies addressing upstream and downstream processes involved in cytokine expression. Molecular design strategies such as codon optimization, vector design, and signal peptide selection are discussed together with process parameters including temperature, inducer concentration, and bioreactor conditions, as well as recovery and purification of biologically active cytokines. Optimal production is often associated using multi-copy vectors driven by the AOX1 promoter, α-factor secretion signals, methanol induction (0.5-1.5% v/v), temperatures below 30 °C, and co-feeding strategies. Downstream purification commonly yields products exceeding 95% purity. Strategies such as PEGylation, albumin fusion, and antibody fusion are also described to improve cytokine stability and half-life. This review integrates and critically analyzes molecular and bioprocessing advances that establish K. phaffii as a powerful platform for recombinant cytokine production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.